Mechanisms of disease: Mendelian disorders of membrane trafficking

Maria Antonietta De Matteis, Alberto Luini

Research output: Contribution to journalArticle

Abstract

It is reasonable to hope that our basic knowledge of membrane trafficking will continue to provide insights into the pathogenesis of mendelian diseases and that studies of these diseases will continue to enhance our understanding of the membrane- trafficking system. In particular, it will be of great interest in this context to learn how to place the genes that are involved in trafficking-related diseases into coherent pathogenetic pathways. Regrettably, the wealth of new insights into the molecular defects in membrane-trafficking disorders has not yet led to a proportionate availability availability of effective therapies. However, in the past few years, the potential of mendelian diseases to drive the process of drug development has been recognized. 52,53 An example in the field of membrane transport is cystic fibrosis. Effective modulators of the folding, trafficking, and activity of CFTR (the chloride channel that is mutated in cystic fibrosis35) have been found through high-throughput screening that was aimed at identifying pharmacologic treatments for this disease. Some of these modulators (e.g., VX-809) are now being tested in clinical trials.54 In addition, interest in the pathways affected in mendelian disorders is being raised further by the recognition that efforts to develop drugs for their treatment might also prove useful in common diseases in which the same pathways might have a pathogenetic role, such as type 2 diabetes and Alzheimer's disease. 52,53

Original languageEnglish
Pages (from-to)927-938
Number of pages12
JournalNew England Journal of Medicine
Volume365
Issue number10
DOIs
Publication statusPublished - Sep 8 2011

Fingerprint

Membranes
Hope
Chloride Channels
Cystic Fibrosis
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Alzheimer Disease
Genes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mechanisms of disease : Mendelian disorders of membrane trafficking. / De Matteis, Maria Antonietta; Luini, Alberto.

In: New England Journal of Medicine, Vol. 365, No. 10, 08.09.2011, p. 927-938.

Research output: Contribution to journalArticle

De Matteis, Maria Antonietta ; Luini, Alberto. / Mechanisms of disease : Mendelian disorders of membrane trafficking. In: New England Journal of Medicine. 2011 ; Vol. 365, No. 10. pp. 927-938.
@article{5938e50b0e8744638bebedd75d56e3b4,
title = "Mechanisms of disease: Mendelian disorders of membrane trafficking",
abstract = "It is reasonable to hope that our basic knowledge of membrane trafficking will continue to provide insights into the pathogenesis of mendelian diseases and that studies of these diseases will continue to enhance our understanding of the membrane- trafficking system. In particular, it will be of great interest in this context to learn how to place the genes that are involved in trafficking-related diseases into coherent pathogenetic pathways. Regrettably, the wealth of new insights into the molecular defects in membrane-trafficking disorders has not yet led to a proportionate availability availability of effective therapies. However, in the past few years, the potential of mendelian diseases to drive the process of drug development has been recognized. 52,53 An example in the field of membrane transport is cystic fibrosis. Effective modulators of the folding, trafficking, and activity of CFTR (the chloride channel that is mutated in cystic fibrosis35) have been found through high-throughput screening that was aimed at identifying pharmacologic treatments for this disease. Some of these modulators (e.g., VX-809) are now being tested in clinical trials.54 In addition, interest in the pathways affected in mendelian disorders is being raised further by the recognition that efforts to develop drugs for their treatment might also prove useful in common diseases in which the same pathways might have a pathogenetic role, such as type 2 diabetes and Alzheimer's disease. 52,53",
author = "{De Matteis}, {Maria Antonietta} and Alberto Luini",
year = "2011",
month = "9",
day = "8",
doi = "10.1056/NEJMra0910494",
language = "English",
volume = "365",
pages = "927--938",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - Mechanisms of disease

T2 - Mendelian disorders of membrane trafficking

AU - De Matteis, Maria Antonietta

AU - Luini, Alberto

PY - 2011/9/8

Y1 - 2011/9/8

N2 - It is reasonable to hope that our basic knowledge of membrane trafficking will continue to provide insights into the pathogenesis of mendelian diseases and that studies of these diseases will continue to enhance our understanding of the membrane- trafficking system. In particular, it will be of great interest in this context to learn how to place the genes that are involved in trafficking-related diseases into coherent pathogenetic pathways. Regrettably, the wealth of new insights into the molecular defects in membrane-trafficking disorders has not yet led to a proportionate availability availability of effective therapies. However, in the past few years, the potential of mendelian diseases to drive the process of drug development has been recognized. 52,53 An example in the field of membrane transport is cystic fibrosis. Effective modulators of the folding, trafficking, and activity of CFTR (the chloride channel that is mutated in cystic fibrosis35) have been found through high-throughput screening that was aimed at identifying pharmacologic treatments for this disease. Some of these modulators (e.g., VX-809) are now being tested in clinical trials.54 In addition, interest in the pathways affected in mendelian disorders is being raised further by the recognition that efforts to develop drugs for their treatment might also prove useful in common diseases in which the same pathways might have a pathogenetic role, such as type 2 diabetes and Alzheimer's disease. 52,53

AB - It is reasonable to hope that our basic knowledge of membrane trafficking will continue to provide insights into the pathogenesis of mendelian diseases and that studies of these diseases will continue to enhance our understanding of the membrane- trafficking system. In particular, it will be of great interest in this context to learn how to place the genes that are involved in trafficking-related diseases into coherent pathogenetic pathways. Regrettably, the wealth of new insights into the molecular defects in membrane-trafficking disorders has not yet led to a proportionate availability availability of effective therapies. However, in the past few years, the potential of mendelian diseases to drive the process of drug development has been recognized. 52,53 An example in the field of membrane transport is cystic fibrosis. Effective modulators of the folding, trafficking, and activity of CFTR (the chloride channel that is mutated in cystic fibrosis35) have been found through high-throughput screening that was aimed at identifying pharmacologic treatments for this disease. Some of these modulators (e.g., VX-809) are now being tested in clinical trials.54 In addition, interest in the pathways affected in mendelian disorders is being raised further by the recognition that efforts to develop drugs for their treatment might also prove useful in common diseases in which the same pathways might have a pathogenetic role, such as type 2 diabetes and Alzheimer's disease. 52,53

UR - http://www.scopus.com/inward/record.url?scp=80052592689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052592689&partnerID=8YFLogxK

U2 - 10.1056/NEJMra0910494

DO - 10.1056/NEJMra0910494

M3 - Article

C2 - 21899453

AN - SCOPUS:80052592689

VL - 365

SP - 927

EP - 938

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -